Tag Archives: Gleevec
Novartis Ruling Reverberates Past India’s Borders
India’s Supreme Court says drug maker Novartis can’t hold onto its patent for the pricey cancer drug Gleevec simply by tweaking its chemical formula. That means generic drug makers can keep making a form of the drug at a tenth
South Korean civil society groups welcome the ruling of the Supreme Court of India
[Novartis defeated in its appeal trial, a triumphant victory of World patients fighting back Patent Exclusivity] Welcome the ruling of the Supreme Court of India 1. The protracted Novartis’ appeal from 2006 for a patent to Gleevec (Leukemia medicine), and
Hearing Update: Novartis argues section 3(d) not intended to address issue of access to medicines
13 September 2012, New Delhi. Mr Subramaniam, senior counsel appearing for Novartis, continued his arguments today. Placing on record the Doha Declaration on TRIPS Agreement and Public Health, Mr Subramaniam said that it is important to bear in mind the
Novartis case: background and update – Supreme Court of India to recommence hearing
Novartis case: background and update – Supreme Court of India to recommence hearing 5 September 2011, New Delhi. Tomorrow, a Division Bench of the Supreme Court of India, comprising Justice Dalveer Bhandari and Justice Deepak Verma, will re-commence the hearing
Current Cases
Novartis AG v. Union of India and Others, SLP (Civil) Nos. 20539–20549 of 2009 In this case, which is presently before the Supreme Court of India, Novartis AG (Novartis) challenges the order of the Intellectual Property Appellate Board (IPAB) rejecting
Hearing Update: Novartis argues that section 3(d) not applicable to its patent application
12 September 2012, New Delhi. Continuing arguments on behalf of Novartis, Mr Gopal Subramaniam, senior counsel, took the Bench through the Complete Specification of Novartis’ patent application for the beta-crystalline form of imatinib mesylate that was filed before the Patent
Novartis Update: Supreme Court adjourns final hearing to 11 September 2012
22 August 2012, New Delhi. As directed by the Supreme Court of India on 10 July 2012, the petition filed by Novartis AG, challenging the Intellectual Property Appellate Board’s rejection of its appeal against the Indian Patent Office’s refusal to
